The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK

医学 布地奈德/福莫特罗 福莫特罗 布地奈德 哮喘 皮质类固醇 内科学 重症监护医学 维持疗法 麻醉 外科 化疗
作者
J. Mark FitzGerald,Sofie Arnetorp,Caitlin Smare,Danny Gibson,Karen Coulton,Kirsty Hounsell,Sarowar Golam,Mohsen Sadatsafavi
出处
期刊:Respiratory Medicine [Elsevier BV]
卷期号:171: 106079-106079 被引量:22
标识
DOI:10.1016/j.rmed.2020.106079
摘要

BackgroundAs-needed budesonide/formoterol is effective in patients with mild asthma for whom low-dose inhaled corticosteroid (ICS) maintenance therapy is appropriate. We assessed the cost-effectiveness of this regimen versus maintenance low-dose ICS plus as-needed short-acting β2-agonist (SABA).MethodsA probabilistic Markov cohort model was developed that simulated time within/outside severe asthma exacerbations, conducted from a UK NHS perspective with a 70-year time horizon. Clinical efficacy inputs were derived from the SYGMA 2 trial. Patients with mild asthma eligible for low-dose maintenance ICS therapy received as-needed budesonide/formoterol 200/6 μg or twice-daily budesonide 200 μg maintenance therapy plus as-needed terbutaline 0.5 mg. A severe exacerbation was defined as worsening asthma requiring systemic corticosteroid use alone/in combination with an emergency department visit, or hospitalisation for acute asthma. Utility values were derived from SYGMA 2 EQ-5D-5L data, and all-cause- and asthma-related mortality, reduction in utility of an exacerbation, and costs were based on published data. The base-case analysis discount rate was 3.5%. Model robustness was evaluated with one-way sensitivity, probabilistic sensitivity, and two scenario analyses.ResultsOn average, as-needed budesonide/formoterol was associated with a £292.99 cost saving and quality-adjusted life year (QALY) gains of 0.001 versus ICS + SABA. At a willingness-to-pay of £20,000/QALY, as-needed budesonide/formoterol had >85% probability of being cost-effective versus ICS + SABA. Key drivers were budesonide/formoterol and budesonide maintenance annual exacerbation rates, mean daily budesonide/formoterol inhalations, and costs and outcomes discount rates.ConclusionsFrom a UK healthcare payer perspective, as-needed budesonide/formoterol is a cost-effective option for the treatment of mild asthma versus regular ICS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ECCE发布了新的文献求助10
刚刚
mjq发布了新的文献求助10
刚刚
无情愫的应助被体贴洋葱采纳,获得10
1秒前
1秒前
1秒前
youyouyeah发布了新的文献求助10
1秒前
WBH36323发布了新的文献求助10
1秒前
逢坂大河发布了新的文献求助10
2秒前
2秒前
陶炳君完成签到 ,获得积分10
2秒前
任虎完成签到,获得积分10
2秒前
3秒前
3秒前
上官若男的应助被如何让人采纳,获得10
3秒前
ycl发布了新的文献求助10
4秒前
徐风拂海棠完成签到 ,获得积分10
4秒前
4秒前
kuku完成签到,获得积分10
4秒前
向连虎发布了新的文献求助10
4秒前
04d的应助被blUe采纳,获得20
5秒前
rose完成签到,获得积分10
5秒前
mm发布了新的文献求助10
5秒前
curry完成签到,获得积分10
5秒前
6秒前
彭于晏的应助被狂野风华采纳,获得10
6秒前
cdercder的应助被Safe采纳,获得10
7秒前
8秒前
爱卿5271完成签到,获得积分10
8秒前
8秒前
Magic麦发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
小张爱科研完成签到 ,获得积分10
9秒前
天天快乐的应助被子木采纳,获得10
9秒前
CipherSage的应助被wwwwwwww采纳,获得10
9秒前
希望天下0贩的0的应助被123采纳,获得10
10秒前
扶风阁主完成签到,获得积分10
10秒前
三月兔发布了新的文献求助10
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949